croup
CROUP
Croup is a viral infection that causes erythema and edema of the tracheal walls and narrowing of the subglottic region. It is often characterized by an acute, rapidly progressing respiratory disease.
It is a medical emergency in children and requiring immediate treatment.
Most common causes are parainfluenza virus 1&2 and respiratory syncytial virus.
Occurrence of symptoms is usually at night and with abrupt onset and improve during daytime.

Croup Signs and Symptoms

Introduction

Croup is often characterized by an acute, rapidly progressing respiratory disease
  • Also referred to as laryngotracheitis, laryngotracheobronchitis, & laryngotracheobronchopneumonitis 
  • Common cause of upper respiratory tract obstruction in children
  • Rarely occurs in adults
  • Often self-limiting but may possibly cause severe respiratory obstruction
  • Develops concurrent w/ coryzal disease

Etiology

  • Most common causes of croup:
    • Parainfluenza virus 1-3 (type 1 being most common) 
    • Respiratory syncytial virus

Signs and Symptoms

  •  Occurrence of symptoms is usually at night & w/ abrupt onset, & improve during daytime
    • Barking cough
    • Dyspnea, w/ possible rapid progression to airway obstruction
    • Hoarse voice
    • Inspiratory stridor may be severe & may herald complete airway obstruction
    • Fever may or may not occur
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 28 Sep 2020
With much remains controversial regarding the possible transmission route of SARS-CoV-2 virus, a study reveals yet another surprise worthy of caution in the hospital setting.
Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.